CoChat
Sign Up
Cited by 56

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment

Mafi, Alireza, Rahmati, Atefe, Babaei Aghdam, Zahra, Salami, Raziyeh, Salami, Marziyeh, Vakili, Omid, Aghadavod, Esmat·2022·Cellular & Molecular Biology Letters
DOI 10.1186/s11658-022-00354-4PMC PMC9347108
Open this paper in CoChat — free account

Abstract

Gliomas are the most lethal primary brain tumors in adults. These highly invasive tumors have poor 5-year survival for patients. Gliomas are principally characterized by rapid diffusion as well as high levels of cellular heterogeneity. However, to date, the exact pathogenic mechanisms, contributing to gliomas remain ambiguous. MicroRNAs (miRNAs), as small noncoding RNAs of about 20 nucleotides in length, are known as chief modulators of different biological processes at both transcriptional and posttranscriptional levels. More recently, it has been revealed that these noncoding RNA molecules have essential roles in tumorigenesis and progression of multiple cancers, including gliomas. Interestingly, miRNAs are able to modulate diverse cancer-related processes such as cell proliferation and apoptosis, invasion and migration, differentiation and stemness, angiogenesis, and drug resistance; thus, impaired miRNAs may result in deterioration of gliomas. Additionally, miRNAs can be secreted into cerebrospinal fluid (CSF), as well as the bloodstream, and transported between normal and tumor cells freely or by exosomes, converting them into potential diagnostic and/or prognostic biomarkers for gliomas. They would also be great therapeutic agents, especially if they could cross the blood–brain barrier (BBB). Accordingly, in the current review, the contribution of miRNAs to glioma pathogenesis is first discussed, then their glioma-related diagnostic/prognostic and therapeutic potential is highlighted briefly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s11658-022-00354-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 13 references

Research works printed but not linked: 226

  1. Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP, Sorensen PH, et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is “dark matter” un-annotated RNA. BMC Biol. 2010;8:149. · DOI
  2. Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1–8. · DOI
  3. Bian Z, Ji W, Xu B, Huo Z, Huang H, Huang J, et al. Noncoding RNAs involved in the STAT3 pathway in glioma. Cancer Cell Int. 2021;21(1):445. · DOI · Paper page
  4. Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, et al. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett. 2022;27(1):1–47. · DOI
  5. Sun W, Li Y, Ma D, Liu Y, Xu Q, Cheng D, et al. ALKBH5 promotes lung fibroblast activation and silica-induced pulmonary fibrosis through miR-320a-3p and FOXM1. Cell Mol Biol Lett. 2022;27(1):1–17. · DOI
  6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54. · DOI · Paper page
  7. Bartel DP. Metazoan microRNAs. Cell. 2018;173(1):20–51. · DOI · Paper page
  8. Shi R, Wang P-Y, Li X-Y, Chen J-X, Li Y, Zhang X-Z, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971. · DOI
  9. Riddick G, Fine HA. Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol. 2011;7(8):439–50. · DOI
  10. Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50(13):2309–18. · DOI
  11. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. · DOI
  12. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, et al. Glial cells in (patho) physiology. J Neurochem. 2012;121(1):4–27. · DOI · Paper page
  13. Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir (Tokyo). 2017;57(7):301–11. · DOI
  14. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML. Anti-cancer therapies in high grade gliomas. Curr Proteomics. 2013;10(3):246–60. · DOI
  15. Salami R, Salami M, Mafi A, Vakili O, Asemi Z. Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms. Cell Commun Signal. 2022;20(1):1–17. · DOI
  16. Goldbrunner R, Ruge M, Kocher M, Lucas CW, Galldiks N, Grau S. The treatment of gliomas in adulthood. Dtsch Arztebl Int. 2018;115(20–21):356.
  17. Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol. 2016;118(1):35–42. · DOI
  18. Weller M, Van Den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–29. · DOI
  19. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-Y, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50. · DOI
  20. Ames H, Halushka MK, Rodriguez FJ. miRNA regulation in gliomas: usual suspects in glial tumorigenesis and evolving clinical applications. J Neuropathol Exp Neurol. 2017;76(4):246–54. · DOI
  21. Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev. 2017;42:14–21. · DOI
  22. Mafi A, Aghadavod E, Mirhosseini N, Mobini M, Asemi Z. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression. J Cell Physiol. 2018;234(1):42–50. · DOI
  23. Homayoonfal M, Asemi Z, Yousefi B. Targeting microRNAs with thymoquinone: a new approach for cancer therapy. Cell Mol Biol Lett. 2021;26(1):1–22. · DOI
  24. Bahmyari S, Jamali Z, Khatami SH, Vakili O, Roozitalab M, Savardashtaki A, et al. MicroRNAs in female infertility: an overview. Cell Biochem Funct. 2021;39(8):955–69. · DOI
  25. Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. · DOI
  26. Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015;4(8):1651–67. · DOI
  27. Wu K, He J, Pu W, Peng Y. The role of exportin-5 in microRNA biogenesis and cancer. Genomics Proteomics Bioinf. 2018;16(2):120–6. · DOI
  28. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019;51:11–7. · DOI
  29. Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World J Biol Chem. 2017;8(1):45–56. · DOI
  30. Chen X, Li X, Guo J, Zhang P, Zeng W. The roles of microRNAs in regulation of mammalian spermatogenesis. J Anim Sci Biotechnol. 2017;8:35. · DOI
  31. Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cell Mol Life Sci. 2018;75(2):177–91. · DOI
  32. Kato M, Castro NE, Natarajan R. MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med. 2013;64:85–94. · DOI
  33. Rokad D, Ghaisas S, Harischandra DS, Jin H, Anantharam V, Kanthasamy A, et al. Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation. Brain Res Bull. 2017;133:60–70. · DOI
  34. Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Velázquez IA, González-Barrios R, Contreras-Espinosa L, et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Therapy. 2020;20:409–20.
  35. Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Transl Res. 2012;5(4):413–22. · DOI
  36. McClelland AD, Kantharidis P. MicroRNA in the development of diabetic complications. Clin Sci (Lond). 2014;126(2):95–110. · DOI
  37. Kato M, Natarajan R. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci. 2015;1353:72–88. · DOI
  38. Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. MiRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9(2):1–14. · DOI
  39. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8. · DOI
  40. Zhou Q, Liu J, Quan J, Liu W, Tan H, Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: a systematic review and meta-analysis. Cancer Sci. 2018;109(9):2651–9. · DOI · Paper page
  41. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010;17(2):215–20. · DOI
  42. Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, et al. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2016;6(2):188–201. · DOI
  43. Zhang X, Li Y, Qi P, Ma Z. Biology of miR-17-92 cluster and its progress in lung cancer. Int J Med Sci. 2018;15(13):1443. · DOI
  44. Mu P, Han Y-C, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17∼ 92 cluster of microRNAs in myc-induced b-cell lymphomas. Genes Dev. 2009;23(24):2806–11. · DOI
  45. Li N, Jiang S, Shi J, Fu R, Wu H, Lu M. Construction of a potential microRNA, transcription factor and mRNA regulatory network in hepatocellular carcinoma. Transl Cancer Res. 2020;9(9):5528. · DOI
  46. Mitsis T, Efthimiadou A, Bacopoulou F, Vlachakis D, Chrousos GP, Eliopoulos E. Transcription factors and evolution: an integral part of gene expression. World Acad Sci J. 2020;2(1):3–8.
  47. Ashrafizadeh M, Zarabi A, Hushmandi K, Moghadam ER, Hashemi F, Daneshi S, et al. C-myc signaling pathway in treatment and prevention of brain tumors. Curr Cancer Drug Targets. 2021;21(1):2–20. · DOI
  48. Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS, Herrick JS. The p53-signaling pathway and colorectal cancer: interactions between downstream p53 target genes and miRNAs. Genomics. 2019;111(4):762–71. · DOI
  49. Jauhari A, Singh T, Singh P, Parmar D, Yadav S. Regulation of miR-34 family in neuronal development. Mol Neurobiol. 2018;55(2):936–45. · DOI
  50. Autin P, Blanquart C, Fradin D. Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancers. 2019;11(10):1530. · DOI
  51. Farooqi AA, Fuentes-Mattei E, Fayyaz S, Raj P, Goblirsch M, Poltronieri P, et al editors. Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. Seminars in cancer biology. Amsterdam: Elsevier; 2019.
  52. Deng D, Liu Z, Du Y. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet. 2010;71:125–76. · DOI
  53. Shi J, Dong B, Cao J, Mao Y, Guan W, Peng Y, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget. 2017;8(16):27582. · DOI
  54. Han W, Shi J, Cao J, Dong B, Guan W. Current advances of long non-coding RNAs mediated by Wnt signaling in glioma. Pathol Res Pract. 2020;216(8): 153008. · DOI
  55. Imai M, Nakamura T, Akiyama T, Horii A. Infrequent somatic mutations of the ICAT gene in various human cancers with frequent 1p-LOH and/or abnormal nuclear accumulation of beta-catenin. Oncol Rep. 2004;12(5):1099–103.
  56. Siegal T. Clinical relevance of prognostic and predictive molecular markers in gliomas. Adv Tech Stand Neurosurg. 2016;43:91–108. · DOI
  57. Holdhoff M. Role of molecular pathology in the treatment of anaplastic gliomas and glioblastomas. J Natl Compr Canc Netw. 2018;16(5s):642–5. · DOI
  58. Jones DTW, Bandopadhayay P, Jabado N. The power of human cancer genetics as revealed by low-grade gliomas. Annu Rev Genet. 2019;53:483–503. · DOI
  59. Keum Y-S, Choi BY. Isocitrate dehydrogenase mutations: new opportunities for translational research. BMB Rep. 2015;48(5):266. · DOI
  60. Ju H-Q, Lin J-F, Tian T, Xie D, Xu R-H. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5(1):1–12. · DOI
  61. Alexander BM, Mehta MP. Role of isocitrate dehydrogenase in glioma. Expert Rev Neurother. 2011;11(10):1399–409. · DOI
  62. Wang T-X, Liang J-Y, Zhang C, Xiong Y, Guan K-L, Yuan H-X. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. Cell Death Dis. 2019;10(10):1–12. · DOI
  63. Zhang L, He L, Lugano R, Roodakker K, Bergqvist M, Smits A, et al. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro Oncol. 2018;20(11):1505–16. · DOI
  64. Han X, Xue X, Zhou H, Zhang G. A molecular view of the radioresistance of gliomas. Oncotarget. 2017;8(59):100931–41. · DOI
  65. Croce CM, Zhang K, Wei Y. Announcing signal transduction and targeted therapy. Signal Transd Target Therapy. 2016;1(1):15006. · DOI
  66. Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med. 2010;31(4):287–329. · DOI
  67. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166–93. · DOI · Paper page
  68. Dang Y, Wei X, Xue L, Wen F, Gu J, Zheng H. Long non-coding RNA in glioma: target miRNA and signaling pathways. Clin Lab. 2018;64(6):887–94.
  69. Noorani I. Genetically engineered mouse models of gliomas: technological developments for translational discoveries. Cancers. 2019;11(9):1335. · DOI
  70. Guzman F, Fazeli Y, Khuu M, Salcido K, Singh S, Benavente CA. Retinoblastoma tumor suppressor protein roles in epigenetic regulation. Cancers. 2020;12(10):2807. · DOI
  71. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. · DOI · Paper page
  72. Olafson LR, Gunawardena M, Nixdorf S, McDonald KL, Rapkins RW. The role of tp53 gain-of-function mutation in multifocal glioblastoma. J Neurooncol. 2020;147(1):37–47. · DOI
  73. Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M. The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Can Res. 2018;78(17):5084–93. · DOI
  74. Fontana R, Ranieri M, La Mantia G, Vivo M. Dual role of the alternative reading frame ARF protein in cancer. Biomolecules. 2019;9(3):87. · DOI
  75. Rahme GJ, Luikart BW, Cheng C, Israel MA. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma. Neuro Oncol. 2018;20(3):332–42. · DOI
  76. Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507. · DOI
  77. Kalhori MR, Arefian E, Fallah Atanaki F, Kavousi K, Soleimani M. miR-548x and miR-4698 controlled cell proliferation by affecting the PI3K/AKT signaling pathway in glioblastoma cell lines. Sci Rep. 2020;10(1):1558. · DOI
  78. Romani M, Pistillo MP, Banelli B. Epigenetic targeting of glioblastoma. Front Oncol. 2018;8:448. · DOI
  79. He J, Jiang Y, Liu L, Zuo Z, Zeng C. Circulating microRNAs as promising diagnostic biomarkers for patients with glioma: a meta-analysis. Front Neurol. 2021;11:8. · DOI
  80. Qu K, Lin T, Pang Q, Liu T, Wang Z, Tai M, et al. Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget. 2016;7(23):33994. · DOI
  81. Møller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol. 2013;47(1):131–44. · DOI
  82. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90(2):144–55. · DOI
  83. Schramedei K, Mörbt N, Pfeifer G, Läuter J, Rosolowski M, Tomm JM, et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene. 2011;30(26):2975–85. · DOI
  84. Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi L, et al. Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep. 2010;24(1):195–201.
  85. Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ, Jeong JA, et al. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene. 2011;30(21):2433–42. · DOI · Paper page
  86. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, et al. MiR-221/222 promote malignant progression of glioma through activation of the AKT pathway. Int J Oncol. 2010;36(4):913–20.
  87. Zhang C-Z, Zhang J-X, Zhang A-L, Shi Z-D, Han L, Jia Z-F, et al. miR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 2010;9(1):1–9. · DOI
  88. Xu H, Zhang Y, Qi L, Ding L, Jiang H, Yu H. NFIX circular RNA promotes glioma progression by regulating miR-34a-5p via notch signaling pathway. Front Mol Neurosci. 2018;11:225. · DOI
  89. Xue F, Shen R, Chen X. Analysis of gene profiles in glioma cells identifies potential genes, miRNAs, and target sites of migratory cells. Tumori. 2015;101(5):542–8. · DOI
  90. Li Q, Wang C, Cai L, Lu J, Zhu Z, Wang C, et al. miR-34a derived from mesenchymal stem cells stimulates senescence in glioma cells by inducing DNA damage. Mol Med Rep. 2019;19(3):1849–57.
  91. Liu S, Jiang T, Zhong Y, Yu Y. miR-210 inhibits cell migration and invasion by targeting the brain-derived neurotrophic factor in glioblastoma. J Cell Biochem. 2019;120(7):11375–82. · DOI
  92. Liu H, Chen C, Zeng J, Zhao Z, Hu Q. MicroRNA-210-3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells. PLoS ONE. 2021;16(7): e0253522. · DOI
  93. Toraih EA, El-Wazir A, Abdallah HY, Tantawy MA, Fawzy MS. Deregulated microRNA signature following glioblastoma irradiation. Cancer Control. 2019;26(1):1073274819847226. · DOI
  94. Shang C, Hong Y, Guo Y, Liu Y-H, Xue Y-X. MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. Med Sci Monit. 2014;20:2571. · DOI
  95. Qin Q, Furong W, Baosheng L. Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 2014;33(1):1–10. · DOI
  96. Zhang G, Chen L, Sun K, Khan AA, Yan J, Liu H, et al. Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression. Tumour Biol. 2016;37(10):13777–88. · DOI
  97. Zhang G, Chen L, Khan AA, Li B, Gu B, Lin F, et al. MiRNA-124-3p/neuropilin-1 (NRP-1) axis plays an important role in mediating glioblastoma growth and angiogenesis. Int J Cancer. 2018;143(3):635–44. · DOI
  98. Xia HF, He TZ, Liu CM, Cui Y, Song PP, Jin XH, et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 2009;23(4–6):347–58. · DOI
  99. Swellam M, Bakr NM, El Magdoub HM, Hamza MS, Ezz El Arab LR. Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. J Mol Neurosci. 2021;71(4):836–44. · DOI
  100. Kuhn DE, Nuovo GJ, Terry AV, Martin MM, Malana GE, Sansom SE, et al. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem. 2010;285(2):1529–43. · DOI
  101. Lee YS, Kim HK, Chung S, Kim K-S, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem. 2005;280(17):16635–41. · DOI
  102. Jiang Y, Ren W, Wang W, Xia J, Gou L, Liu M, et al. Inhibitor of β-catenin and TCF (ICAT) promotes cervical cancer growth and metastasis by disrupting e-cadherin/β-catenin complex. Oncol Rep. 2017;38(5):2597–606. · DOI
  103. Zhang K, Zhu S, Liu Y, Dong X, Shi Z, Zhang A, et al. ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity. Cancer Lett. 2015;357(1):404–11. · DOI
  104. Zhang Y, Li T, Guo P, Kang J, Wei Q, Jia X, et al. MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression. Sci Rep. 2014;4:6248. · DOI
  105. Lin WH, Li J, Zhang B, Liu LS, Zou Y, Tan JF, et al. MicroRNA-1301 induces cell proliferation by downregulating ICAT expression in breast cancer. Biomed Pharmacother. 2016;83:177–85. · DOI
  106. Zhou J, Du G, Fu H. MiR-296-3p promotes the proliferation of glioblastoma cells by targeting ICAT. Mol Med Rep. 2020;21(5):2151–61.
  107. Lee H, Hwang SJ, Kim HR, Shin CH, Choi KH, Joung JG, et al. Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta. 2016;1859(4):599–611. · DOI
  108. Shin J, Shin Y, Oh SM, Yang H, Yu WJ, Lee JP, et al. MiR-29b controls fetal mouse neurogenesis by regulating ICAT-mediated Wnt/β-catenin signaling. Cell Death Dis. 2014;5(10): e1473. · DOI
  109. Chen J, Wu X, Xing Z, Ma C, Xiong W, Zhu X, et al. FOXG1 expression is elevated in glioma and inhibits glioma cell apoptosis. J Cancer. 2018;9(5):778–83. · DOI
  110. Shibata M, Kurokawa D, Nakao H, Ohmura T, Aizawa S. MicroRNA-9 modulates Cajal-Retzius cell differentiation by suppressing FOXG1 expression in mouse medial pallium. J Neurosci. 2008;28(41):10415–21. · DOI · Paper page
  111. Zhen J, Zhang H, Dong H, Tong X. MiR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1. Oncol Lett. 2020;20(2):2007–15. · DOI
  112. Xu YF, Liu J, Wang J, Guo YC, Shen YZ. MiR-186 promotes the apoptosis of glioma U87 cells by down-regulating the expression of Smad6. Eur Rev Med Pharmacol Sci. 2020;24(14):7681–9.
  113. Li C, Feng S, Chen L. MicroRNA-142-3p inhibits proliferation and induces apoptosis by targeting the high-mobility group box 1 via the Wnt/β-catenin signaling pathway in glioma. Int J Clin Exp Pathol. 2018;11(9):4493–502.
  114. Gao C, Shen J, Meng Z-X, He X-F. Sevoflurane inhibits glioma cells proliferation and metastasis through miRNA-124-3p/ROCK1 axis. Pathol Oncol Res. 2020;26(2):947–54. · DOI
  115. Singh A, Singh AK, Giri R, Kumar D, Sharma R, Valis M, et al. The role of microRNA-21 in the onset and progression of cancer. Future Med Chem. 2021;13(21):1885–906. · DOI
  116. Aufiero S, Reckman YJ, Tijsen AJ, Pinto YM, Creemers EE. Circrnaprofiler: an R-based computational framework for the downstream analysis of circular RNAs. BMC Bioinform. 2020;21(1):1–9. · DOI
  117. Mummidi S, Das NA, Carpenter AJ, Yoshida T, Yariswamy M, Mostany R, et al. RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation. J Cell Physiol. 2019;234(12):22242–59. · DOI
  118. Shen K-H, Hung J-H, Liao Y-C, Tsai S-T, Wu M-J, Chen P-S. Sinomenine inhibits migration and invasion of human lung cancer cell through downregulating expression of miR-21 and MMPs. Int J Mol Sci. 2020;21(9):3080. · DOI
  119. Guan N, Wang R, Feng X, Li C, Guo W. Long non-coding RNA NBAT1 inhibits the progression of glioma through the miR-21/SOX7 axis. Oncol Lett. 2020;20(3):3024–34. · DOI
  120. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97–117. · DOI
  121. Löffek S, Schilling O, Franzke CW. Series “matrix metalloproteinases in lung health and disease”: biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;38(1):191–208. · DOI
  122. Peng G, Liu Y, Yang C, Shen C. MicroRNA-25 promotes cell proliferation, migration and invasion in glioma by directly targeting cell adhesion molecule 2. Exp Ther Med. 2022;23(1):16. · DOI
  123. Liu Y, Jiang K, Zhi T, Xu X. MiR-720 is a key regulator of glioma migration and invasion by controlling TARSL2 expression. Hum Cell. 2021;34(5):1504–16. · DOI
  124. Kwon NH, Fox PL, Kim S. Aminoacyl-tRNA synthetases as therapeutic targets. Nat Rev Drug Discov. 2019;18(8):629–50. · DOI
  125. Suh JH, Park MC, Goughnour PC, Min BS, Kim SB, Lee WY, et al. Plasma lysyl-tRNA synthetase 1 (KARS1) as a novel diagnostic and monitoring biomarker for colorectal cancer. J Clin Med. 2020;9(2):533. · DOI
  126. Nam SH, Kim D, Lee D, Lee H-M, Song D-G, Jung JW, et al. Lysyl-tRNA synthetase–expressing colon spheroids induce M2 macrophage polarization to promote metastasis. J Clin Investig. 2018;128(11):5034–55. · DOI
  127. Nam SH, Kang M, Ryu J, Kim H-J, Kim D, Kim DG, et al. Suppression of lysyl-tRNA synthetase, KRS, causes incomplete epithelial-mesenchymal transition and ineffective cell-extracellular matrix adhesion for migration. Int J Oncol. 2016;48(4):1553–60. · DOI
  128. Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, et al. MiR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett. 2013;339(2):260–9. · DOI
  129. Yang B, Xia S, Ye X, Jing W, Wu B. MiR-379-5p targets microsomal glutathione transferase 1 (MGST1) to regulate human glioma in cell proliferation, migration and invasion and epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun. 2021;568:8–14. · DOI
  130. De Luca A, Federici L, De Canio M, Stella L, Caccuri AM. New insights into the mechanism of JNK1 inhibition by glutathione transferase P1–1. Biochemistry. 2012;51(37):7304–12. · DOI
  131. Cheng SY, Chen NF, Wen ZH, Yao ZK, Tsui KH, Kuo HM, et al. Glutathione S-transferase M3 is associated with glycolysis in intrinsic temozolomide-resistant glioblastoma multiforme cells. Int J Mol Sci. 2021;22(13):807. · DOI
  132. Shen H, Xu L, You C, Tang H, Wu H, Zhang Y, et al. MiR-665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1. Oncol Lett. 2021;21(2):156. · DOI
  133. Shi X, Wang J, Lei Y, Cong C, Tan D, Zhou X. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (review). Mol Med Rep. 2019;19(6):4529–35.
  134. Mirzadeh Azad F, Naeli P, Malakootian M, Baradaran A, Tavallaei M, Ghanei M, et al. Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors. Gene. 2016;577(2):221–6. · DOI
  135. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, et al. PI3K/AKT/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440–50. · DOI
  136. Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, et al. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget. 2017;8(24):38755–66. · DOI
  137. Xu B, Mei J, Ji W, Huo Z, Bian Z, Jiao J, et al. MicroRNAs involved in the EGFR pathway in glioblastoma. Biomed Pharmacother. 2021;134: 111115. · DOI
  138. Zhong X, Tang J, Li H, Shi X, Wu Y, Xia D, et al. MiR-3175 promotes epithelial-mesenchymal transition by targeting Smad7 in human conjunctiva and pterygium. FEBS Lett. 2020;594(7):1207–17. · DOI
  139. Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (eag1). Eur J Cancer. 2013;49(3):710–24. · DOI
  140. Xiong W, Ran J, Jiang R, Guo P, Shi X, Li H, et al. MiRNA-320a inhibits glioma cell invasion and migration by directly targeting aquaporin 4. Oncol Rep. 2018;39(4):1939–47.
  141. Zhang G, Chen L, Khan AA, Li B, Gu B, Lin F, et al. MiRNA-124-3p/neuropilin-1 (NRP-1) axis plays an important role in mediating glioblastoma growth and angiogenesis. Int J Cancer. 2018;143(3):635–44. · DOI
  142. Buruiană A, Florian ȘI, Florian AI, Timiș T-L, Mihu CM, Miclăuș M, et al. The roles of miRNA in glioblastoma tumor cell communication: diplomatic and aggressive negotiations. Int J Mol Sci. 2020;21(6):1950. · DOI
  143. Yuan M, Da Silva ACA, Arnold A, Okeke L, Ames H, Correa-Cerro LS, et al. MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep. 2018;8(1):1–14. · DOI
  144. Smits M, Wurdinger T, van het Hof B, Drexhage JA, Geerts D, Wesseling P, et al. Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. FASEB J. 2012;26(6):2639–47. · DOI
  145. Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P, et al. MiR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci. 2014;111(1):291–6. · DOI
  146. Malekpour Afshar R, Mollaei HR, Shokrizadeh M, Iranpour M. Evaluation expression of microRNA-93 and integrin β8 in different types of glioma tumors. Asian Pac J Cancer Prev. 2017;18(3):603–8.
  147. Yi G-Z, Huang G, Guo M, Zhang X, Wang H, Deng S, et al. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain. 2019;142(8):2352–66. · DOI
  148. Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir. 2018;58(10):405. · DOI
  149. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. · DOI · Paper page
  150. Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013;16(3–5):47–59. · DOI
  151. Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M, et al. Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic review and meta-analysis. Cells. 2019;8:10. · DOI
  152. Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet. 2019;11(1):25. · DOI
  153. Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. · DOI
  154. Li G, Lan Q. Exosome-mediated transfer of CIRC-GLIS3 enhances temozolomide resistance in glioma cells through the miR-548m/MED31 axis. Cancer Biother Radiopharm. 2021. · DOI
  155. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010;1352:255–64. · DOI
  156. Movahedpour A, Khatami SH, Khorsand M, Salehi M, Savardashtaki A, Mirmajidi SH, et al. Exosomal noncoding RNAs: key players in glioblastoma drug resistance. Mol Cell Biochem. 2021;476(11):4081–92. · DOI
  157. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012;40(1):119–29.
  158. Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y, et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 2012;27(3):854–60.
  159. She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G, et al. MiR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep. 2014;32(3):957–64. · DOI
  160. She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G, et al. MiR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol. 2014;31(4):892. · DOI
  161. Chen Q, Wang W, Chen S, Chen X, Lin Y. MiR-29a sensitizes the response of glioma cells to temozolomide by modulating the p53/MDM2 feedback loop. Cell Mol Biol Lett. 2021;26(1):1–15. · DOI
  162. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010;296(2):241–8. · DOI
  163. Chen G, Chen Z, Zhao H. MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. J Cell Mol Med. 2020;24(9):5363–74. · DOI
  164. Zhou X, Wu W, Zeng A, Nie E, Jin X, Yu T, et al. MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53. Oncotarget. 2017;8(41):71080–94. · DOI
  165. Wang H, Ren S, Xu Y, Miao W, Huang X, Qu Z, et al. MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells. Anticancer Drugs. 2019;30(1):81–8. · DOI
  166. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005;24(17):2776–86. · DOI
  167. Fan TY, Wang H, Xiang P, Liu YW, Li HZ, Lei BX, et al. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int J Clin Exp Pathol. 2014;7(10):6662–70.
  168. Zhi T, Yu T, Pan M, Nie E, Wu W, Wang X, et al. EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma. Oncotarget. 2017;8(56):96239–48. · DOI
  169. Kan MC, Oruganty-Das A, Cooper-Morgan A, Jin G, Swanger SA, Bassell GJ, et al. CPEB4 is a cell survival protein retained in the nucleus upon ischemia or endoplasmic reticulum calcium depletion. Mol Cell Biol. 2010;30(24):5658–71. · DOI
  170. Li C, Feng S, Chen L. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/AKT pathway. Mol Cell Biochem. 2021;476(2):699–713. · DOI
  171. Morgenroth A, Vogg AT, Ermert K, Zlatopolskiy B, Mottaghy FM. Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation. Oncotarget. 2014;5(14):5483–93. · DOI
  172. Jin J, Grigore F, Chen CC, Li M. Self-renewal signaling pathways and differentiation therapies of glioblastoma stem cells (review). Int J Oncol. 2021;59(1):1–11. · DOI
  173. Diana A, Gaido G, Murtas D. MicroRNA signature in human normal and tumoral neural stem cells. Int J Mol Sci. 2019;20(17):4123. · DOI
  174. Sana J, Busek P, Fadrus P, Besse A, Radova L, Vecera M, et al. Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. Sci Rep. 2018;8(1):2836. · DOI
  175. Balachandran AA, Larcher LM, Chen S, Veedu RN. Therapeutically significant microRNAs in primary and metastatic brain malignancies. Cancers (Basel). 2020;12(9):1–9. · DOI
  176. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013;4(5):665–76. · DOI
  177. Bier A, Hong X, Cazacu S, Goldstein H, Rand D, Xiang C, et al. MiR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles. Cell Death Dis. 2020;11(10):899. · DOI
  178. Bradshaw A, Wickremesekera A, Brasch HD, Chibnall AM, Davis PF, Tan ST, et al. Cancer stem cells in glioblastoma multiforme. Front Surg. 2016;3:48.
  179. Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother. 2015;15(7):741–52. · DOI
  180. Huang W, Zhong Z, Luo C, Xiao Y, Li L, Zhang X, et al. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Theranostics. 2019;9(19):5497–516. · DOI
  181. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes OCT4, SOX2 and Nanog in human gliomas. Histopathology. 2011;59(4):763–75. · DOI
  182. Peng L, Ming Y, Zhang L, Zhou J, Xiang W, Zeng S, et al. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway. FASEB J. 2020;34(4):5128–43. · DOI
  183. Chao CC, Kan D, Lu KS, Chien CL. The role of microRNA-30c in the self-renewal and differentiation of C6 glioma cells. Stem Cell Res. 2015;14(2):211–23. · DOI
  184. Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, et al. MiR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest. 2014;124(10):4489–502. · DOI
  185. Zhang D, Yang G, Chen X, Li C, Wang L, Liu Y, et al. MiR-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells. J Mol Neurosci. 2014;53:637–44. · DOI
  186. Kopkova A, Sana J, Fadrus P, Slaby O. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin Chem Lab Med. 2018;56(6):869–79. · DOI
  187. Piwecka M, Rolle K, Belter A, Barciszewska AM, Żywicki M, Michalak M, et al. Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 2015;9(7):1324–40. · DOI · Paper page
  188. Xiao Y, Zhang L, Song Z, Guo C, Zhu J, Li Z, et al. Potential diagnostic and prognostic value of plasma circulating microRNA-182 in human glioma. Med Sci Monit. 2016;22:855–62. · DOI
  189. Santangelo A, Imbrucè P, Gardenghi B, Belli L, Agushi R, Tamanini A, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018;136(1):51–62. · DOI
  190. Ivo D’Urso P, Fernando D’Urso O, Damiano Gianfreda C, Mezzolla V, Storelli C, Marsigliante S. MiR-15b and miR-21 as circulating biomarkers for diagnosis of glioma. Curr Genomics. 2015;16(5):304–11. · DOI
  191. Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, Quan K, et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017;8(40):68769–79. · DOI
  192. Yuan J, Zheng Z, Zheng Y, Lu X, Xu L, Lin L. MicroRNA-328 is a favorable prognostic marker in human glioma via suppressing invasive and proliferative phenotypes of malignant cells. Int J Neurosci. 2016;126(2):145–53. · DOI
  193. Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, Gardiman MP, et al. Circulating microRNAs predict survival of patients with tumors of glial origin. EBioMedicine. 2018;30:105–12. · DOI
  194. Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016;124(1):122–8. · DOI
  195. Hayes J, Thygesen H, Gregory W, Westhead DR, French PJ, Van Den Bent MJ, et al. A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Mol Oncol. 2016;10(8):1296–304. · DOI
  196. Son JC, Jeong HO, Park D, No SG, Lee EK, Lee J, et al. MiR-10a and miR-204 as a potential prognostic indicator in low-grade gliomas. Cancer Inform. 2017;16:1176935117702878. · DOI
  197. Zhang Y, Chen J, Xue Q, Wang J, Zhao L, Han K, et al. Prognostic significance of microRNAs in glioma: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:4015969.
  198. Niyazi M, Zehentmayr F, Niemöller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, et al. MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol. 2011;6:153. · DOI
  199. Yuan Y, Zhang H, Liu X, Lu Z, Li G, Lu M, et al. MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer Genome Atlas. Oncotarget. 2017;8(35):58386–93. · DOI
  200. Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 2015;9(3):704–14. · DOI

200 of 226 shown

Cited by

Sorted by citations

See all 56

Metadata

Authors
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E.
ORCID
Aghadavod, Esmat
Venue
Cellular & Molecular Biology Letters
Publisher
Springer Science and Business Media LLC
Published
2022-08-03
Volume
27
Issue
1
ISSN
  • 1425-8153
  • 1689-1392
DOI
10.1186/s11658-022-00354-4
PMC
PMC9347108
Cited by
56
References
13
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review